Mohamed Abou-el-Enein

Title(s)Associate Professor of Medicine (Clinical Scholar), Pediatrics, and Stem Cell Biology & Regenerative Medicine
SchoolKeck School of Medicine of Usc
Address1450 Biggy Street
Health Sciences Campus
Los Angeles CA 90033
ORCID ORCID Icon0000-0003-2903-9040 Additional info
vCardDownload vCard
    Other Positions
    Title(s)Executive Director, Joint USC/CHLA Cell Therapy Program


    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy. Blood Cancer Discov. 2024 Jul 01; 5(4):249-257. Abou-El-Enein M. PMID: 38713831; PMCID: PMC11215381.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    2. Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells. Blood. 2024 Jun 20; 143(25):2599-2611. Kath J, Franke C, Drosdek V, Du W, Glaser V, Fuster-Garcia C, Stein M, Zittel T, Schulenberg S, Porter CE, Andersch L, Künkele A, Alcaniz J, Hoffmann J, Abken H, Abou-El-Enein M, Pruß A, Suzuki M, Cathomen T, Stripecke R, Volk HD, Reinke P, Schmueck-Henneresse M, Wagner DL. PMID: 38493479; PMCID: PMC11196866.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    3. Biomanufacturing in gene and cell therapy. Mol Ther Methods Clin Dev. 2024 Jun 13; 32(2):101261. Stone D, Wang X, Abou-El-Enein M. PMID: 38846336; PMCID: PMC11153238.
      View in: PubMed   Mentions:
    4. Disseminating transformative gene and cell therapy research. Mol Ther Methods Clin Dev. 2024 Jun 13; 32(2):101246. Abou-El-Enein M. PMID: 38680554; PMCID: PMC11047778.
      View in: PubMed   Mentions:
    5. Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Adv. 2024 01 23; 8(2):484-496. Choe JH, Yu T, Abramson JS, Abou-El-Enein M. PMID: 38153350; PMCID: PMC10837180.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    6. Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells. bioRxiv. 2023 Nov 14. Kath J, Franke C, Drosdek V, Du W, Glaser V, Fuster-Garcia C, Stein M, Zittel T, Schulenberg S, Porter CE, Andersch L, Künkele A, Alcaniz J, Hoffmann J, Abken H, Abou-El-Enein M, Pruß A, Suzuki M, Cathomen T, Stripecke R, Volk HD, Reinke P, Schmueck-Henneresse M, Wagner DL. PMID: 38116030; PMCID: PMC10729737.
      View in: PubMed   Mentions:
    7. Bringing base editing to the clinic: The next generation of genome editors. Mol Ther Methods Clin Dev. 2023 Dec 14; 31:101138. Flugel CL, Abou-El-Enein M. PMID: 38027069; PMCID: PMC10654602.
      View in: PubMed   Mentions:
    8. Advancing in vivo genome editing: B cell engineering via adenoviral delivery systems. Mol Ther. 2023 09 06; 31(9):2554-2556. Cadinanos-Garai A, Abou-El-Enein M. PMID: 37611582; PMCID: PMC10492014.
      View in: PubMed   Mentions:    Fields:    Translation:Cells
    9. CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products. Blood Adv. 2023 08 08; 7(15):4124-4134. Kath J, Du W, Martini S, Elsallab M, Franke C, Hartmann L, Drosdek V, Glaser V, Stein M, Schmueck-Henneresse M, Reinke P, Volk HD, Abou-El-Enein M, Wagner DL. PMID: 37196643; PMCID: PMC10388728.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    10. Non-viral chimeric antigen receptor (CAR) T cells going viral. Immunooncol Technol. 2023 Jun; 18:100375. Balke-Want H, Keerthi V, Cadinanos-Garai A, Fowler C, Gkitsas N, Brown AK, Tunuguntla R, Abou-El-Enein M, Feldman SA. PMID: 37124148; PMCID: PMC10139995.
      View in: PubMed   Mentions: 15  
    11. Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Gene Ther. 2023 06; 30(6):845-854. Elsallab M, Ellithi M, Hempel S, Abdel-Azim H, Abou-El-Enein M. PMID: 36750666; PMCID: PMC10281866.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    12. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. JAMA Netw Open. 2022 12 01; 5(12):e2245956. Choe JH, Abdel-Azim H, Padula WV, Abou-El-Enein M. PMID: 36520440; PMCID: PMC9856352.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    13. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023 01; 20(1):49-62. Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M. PMID: 36418477; PMCID: PMC10278599.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansAnimalsCells
    14. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022 05; 19(5):342-355. Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-El-Enein M. PMID: 35318469.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCells
    15. Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. Mol Ther. 2022 06 01; 30(6):2298-2314. Landwehr-Kenzel S, Müller-Jensen L, Kuehl JS, Abou-El-Enein M, Hoffmann H, Muench S, Kaiser D, Roemhild A, von Bernuth H, Voeller M, Schmueck-Henneresse M, Gruhn B, Stervbo U, Babel N, Volk HD, Reinke P. PMID: 35240319; PMCID: PMC9171381.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    16. The Value of CAR-T-cell Immunotherapy in Cancer. The EBMT/EHA CAR-T Cell Handbook. 2022. Abou-el-Enein M, Gauthier J. View Publication.
    17. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov. 2021 Sep; 2(5):408-422. Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. PMID: 34568831; PMCID: PMC8462122.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    18. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev. 2021 Sep 10; 22:11-14. Abou-El-Enein M, Angelis A, Appelbaum FR, Andrews NC, Bates SE, Bierman AS, Brenner MK, Cavazzana M, Caligiuri MA, Clevers H, Cooke E, Daley GQ, Dzau VJ, Ellis LM, Fineberg HV, Goldstein LSB, Gottschalk S, Hamburg MA, Ingber DE, Kohn DB, Krainer AR, Maus MV, Marks P, Mummery CL, Pettigrew RI, Rutter JL, Teichmann SA, Terzic A, Urnov FD, Williams DA, Wolchok JD, Lawler M, Turtle CJ, Bauer G, Ioannidis JPA. PMID: 34377737; PMCID: PMC8322039.
      View in: PubMed   Mentions: 6  
    19. Unproven stem cell interventions: A global public health problem requiring global deliberation. Stem Cell Reports. 2021 06 08; 16(6):1435-1445. Master Z, Matthews KRW, Abou-El-Enein M. PMID: 34107243; PMCID: PMC8190665.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    20. Detection of SARS-CoV-2-specific memory B cells to delineate long-term COVID-19 immunity. Allergy. 2021 08; 76(8):2595-2599. Thieme CJ, Abou-El-Enein M, Fritsche E, Anft M, Paniskaki K, Skrzypczyk S, Doevelaar A, Elsallab M, Brindle N, Blazquez-Navarro A, Seibert FS, Meister TL, Pfaender S, Steinmann E, Witzke O, Westhoff TH, Stervbo U, Heine G, Roch T, Babel N. PMID: 33764510; PMCID: PMC8251309.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    21. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021 06; 18(6):379-393. Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, Wayne AS, Abou-El-Enein M. PMID: 33633361; PMCID: PMC8923136.
      View in: PubMed   Mentions: 117     Fields:    Translation:Humans
    22. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. BMJ. 2020 10 21; 371:m3734. Roemhild A, Otto NM, Moll G, Abou-El-Enein M, Kaiser D, Bold G, Schachtner T, Choi M, Oellinger R, Landwehr-Kenzel S, Juerchott K, Sawitzki B, Giesler C, Sefrin A, Beier C, Wagner DL, Schlickeiser S, Streitz M, Schmueck-Henneresse M, Amini L, Stervbo U, Babel N, Volk HD, Reinke P. PMID: 33087345; PMCID: PMC7576328.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCellsCTClinical Trials
    23. COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a+. Mol Ther. 2020 12 02; 28(12):2691-2702. Anft M, Paniskaki K, Blazquez-Navarro A, Doevelaar A, Seibert FS, Hölzer B, Skrzypczyk S, Kohut E, Kurek J, Zapka J, Wehler P, Kaliszczyk S, Bajda S, Thieme CJ, Roch T, Konik MJ, Berger MM, Brenner T, Kölsch U, Meister TL, Pfaender S, Steinmann E, Tempfer C, Watzl C, Dolff S, Dittmer U, Abou-El-Enein M, Westhoff TH, Witzke O, Stervbo U, Babel N. PMID: 33186542; PMCID: PMC7543694.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsPHPublic Health
    24. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies. Mol Ther. 2020 10 07; 28(10):2108-2110. Feucht J, Abou-El-Enein M. PMID: 32841587; PMCID: PMC7545000.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    25. Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals. Mol Ther Methods Clin Dev. 2020 Sep 11; 18:269-279. Elsallab M, Bravery CA, Kurtz A, Abou-El-Enein M. PMID: 32637456; PMCID: PMC7327881.
      View in: PubMed   Mentions: 18  
    26. CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncol. 2020 02; 21(2):e104-e116. Elsallab M, Levine BL, Wayne AS, Abou-El-Enein M. PMID: 32007196; PMCID: PMC7841982.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    27. Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy. Trends Biotechnol. 2020 10; 38(10):1099-1112. Fritsche E, Volk HD, Reinke P, Abou-El-Enein M. PMID: 31982150.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimalsCells
    28. Cell and Gene Therapy Trials: Are We Facing an 'Evidence Crisis'? EClinicalMedicine. 2019 Jan; 7:13-14. Abou-El-Enein M, Hey SP. PMID: 31193634; PMCID: PMC6537560.
      View in: PubMed   Mentions: 13  
    29. Linking Scattered Stem Cell-Based Data to Advance Therapeutic Development. Trends Mol Med. 2019 01; 25(1):8-19. Kurtz A, Elsallab M, Sanzenbacher R, Abou-El-Enein M. PMID: 30497944.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    30. Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity. ESC Heart Fail. 2018 10; 5(5):818-829. Van Linthout S, Elsanhoury A, Klein O, Sosnowski M, Miteva K, Lassner D, Abou-El-Enein M, Pieske B, Kühl U, Tschöpe C. PMID: 30099854; PMCID: PMC6165949.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    31. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med. 2018 09; 7(9):676-685. Bauer G, Elsallab M, Abou-El-Enein M. PMID: 30063299; PMCID: PMC6127222.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    32. The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage? Trends Biotechnol. 2019 02; 37(2):120-123. Cathomen T, Schüle S, Schüßler-Lenz M, Abou-El-Enein M. PMID: 30017092.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    33. Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. Mol Ther. 2018 05 02; 26(5):1172-1176. Abou-El-Enein M, Grainger DW, Kili S. PMID: 29685384; PMCID: PMC5993957.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    34. Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation. Adv Drug Deliv Rev. 2018 Nov - Dec; 136-137:97-104. Fortunato A, Grainger DW, Abou-El-Enein M. PMID: 29408180.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    35. Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment. Cell Stem Cell. 2017 10 05; 21(4):427-430. Abou-El-Enein M, Cathomen T, Ivics Z, June CH, Renner M, Schneider CK, Bauer G. PMID: 28985524.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    36. Accelerating Patients' Access to Advanced Therapies in the EU. Mol Ther Methods Clin Dev. 2017 Dec 15; 7:15-19. Elsanhoury A, Sanzenbacher R, Reinke P, Abou-El-Enein M. PMID: 28971109; PMCID: PMC5609878.
      View in: PubMed   Mentions: 8  
    37. The path to successful commercialization of cell and gene therapies: empowering patient advocates. Cytotherapy. 2017 02; 19(2):293-298. Bauer G, Abou-El-Enein M, Kent A, Poole B, Forte M. PMID: 27956199.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    38. Clinical Development of Cell Therapies: Setting the Stage for Academic Success. Clin Pharmacol Ther. 2017 Jan; 101(1):35-38. Abou-El-Enein M, Volk HD, Reinke P. PMID: 27709611.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    39. Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell Stem Cell. 2016 09 01; 19(3):293-7. Abou-El-Enein M, Elsanhoury A, Reinke P. PMID: 27588746.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    40. Strategies for Derisking Translational Processes for Biomedical Technologies. Trends Biotechnol. 2017 02; 35(2):100-108. Abou-El-Enein M, Duda GN, Gruskin EA, Grainger DW. PMID: 27499276.
      View in: PubMed   Mentions: 10     Fields:    Translation:PHPublic Health
    41. Putting a price tag on novel autologous cellular therapies. Cytotherapy. 2016 08; 18(8):1056-1061. Abou-El-Enein M, Bauer G, Medcalf N, Volk HD, Reinke P. PMID: 27288308.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    42. Deciphering the EU clinical trials regulation. Nat Biotechnol. 2016 Mar; 34(3):231-3. Abou-El-Enein M, Schneider CK. PMID: 26963541.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    43. Gene therapy: a possible future standard for HIV care. Trends Biotechnol. 2015 Jul; 33(7):374-6. Abou-El-Enein M, Bauer G, Reinke P. PMID: 26088914.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    44. The business case for cell and gene therapies. Nat Biotechnol. 2014 Dec; 32(12):1192-3. Abou-El-Enein M, Bauer G, Reinke P. PMID: 25489833.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    45. A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends Mol Med. 2014 Nov; 20(11):632-42. Abou-El-Enein M, Bauer G, Reinke P, Renner M, Schneider CK. PMID: 25262540.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    46. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy. 2013 Mar; 15(3):362-83. Abou-El-Enein M, Römhild A, Kaiser D, Beier C, Bauer G, Volk HD, Reinke P. PMID: 23579061.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    Mohamed's Networks
    Concepts (132)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (6)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.